The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
GLP-1-based therapies, including albiglutide, may be associated with cardiovascular benefits in Type 2 diabetes, but many comparisons for mortality outcomes were not statistically significant.
Where it sits
this study against the rest of the albiglutide corpusSummary and findings
This study assessed the impact of GLP-1-based therapies on cardiovascular outcomes in adults with Type 2 diabetes mellitus (T2DM) through a systematic review and network meta-analysis. Albiglutide was specifically noted for reducing non-fatal myocardial infarction compared to placebo. The study included 15 trials with a total of 97,173 participants.
Abstract
<h4>Aims</h4>To provide updated agent-level comparative estimates of GLP-1-based therapies for cardiovascular outcomes in adults with Type 2 diabetes mellitus (T2DM) using a hazard ratio (HR)-based systematic review and network meta-analysis (NMA).<h4>Methods</h4>PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes. Pairwise meta-analyses and a frequentist random-effects NMA were performed for all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non-fatal myocardial infarction (MI) and non-fatal stroke.<h4>Results</h4>Fifteen trials involving 97,173 participants were included. In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE. In the NMA, mortality estimates for several agents favoured benefit, although most comparisons were not statistically significant. For MACE, efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles. Albiglutide reduced non-fatal MI versus placebo, whereas non-fatal stroke estimates were imprecise.<h4>Conclusions</h4>GLP-1-based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class-level benefit, whereas between-agent differences were more evident for MACE than for mortality outcomes in the NMA.
Background
This paper addresses the cardiovascular outcomes associated with GLP-1-based therapies in adults with Type 2 diabetes mellitus (T2DM). Prior research has indicated potential cardiovascular benefits of GLP-1 receptor agonists, but comparative effectiveness among different agents was not well established. This study aims to provide updated estimates and insights into the cardiovascular profiles of these therapies.
Methods
The study utilized a systematic review and network meta-analysis design, searching databases including PubMed, Cochrane Library, and Scopus up to December 2025. It included randomized controlled trials that evaluated GLP-1-based therapies in adults with T2DM and reported time-to-event cardiovascular outcomes. The primary outcomes measured were all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non-fatal myocardial infarction (MI), and non-fatal stroke.
Results
The analysis included 15 trials with a total of 97,173 participants. Pairwise placebo-controlled analyses showed significant reductions in all-cause mortality, cardiovascular mortality, and MACE with GLP-1-based therapies. In the network meta-analysis, while several agents showed favorable mortality estimates, most comparisons did not reach statistical significance. Albiglutide specifically reduced non-fatal MI compared to placebo, but estimates for non-fatal stroke were imprecise.
Interpretation
The findings suggest that GLP-1-based therapies may offer cardiovascular benefits in T2DM, particularly regarding MACE. However, the lack of statistical significance in many mortality comparisons raises questions about the robustness of these findings. The study's reliance on randomized controlled trials helps mitigate some confounding factors, but the imprecision in certain estimates, especially for non-fatal stroke, limits definitive conclusions.
Key findings
- 97,173 participants included across 15 trials.
- Albiglutide reduced non-fatal myocardial infarction versus placebo.
- Most comparisons for mortality outcomes were not statistically significant.
- Pairwise analyses indicated significant reductions in all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events.
Limitations
- Most comparisons for mortality outcomes were not statistically significant.
- Study relies on data from randomized controlled trials.
- Imprecise estimates for non-fatal stroke.